Nervous System Diseases

Heart and Blood Diseases

All Conditions

Symptoms and General Pathology

Wounds and Injuries

Musculoskeletal Diseases

Neoplasms

Stroke

Hypoxia

Brain Injuries

Pain

Shoulder Pain

Brain Neoplasms

Hypoxia, Brain

Brain Diseases

Central Nervous System Diseases

Arthralgia

Joint Diseases

Neurologic Manifestations

Craniocerebral Trauma

Trauma, Nervous System

Signs and Symptoms, Respiratory

3,000 pulses per time, low energy under 0.3 mJ/mm\^2, tolerable range

Extracorporeal shockwave therapy 6 times during 2 weeks

Extracorporeal shockwave therapy

MinYoung Kim, MD, PhD

MinYoung Kim, MD,PhD

This study aimed to investigate the efficacy and safety of extracorporeal shockwave therapy (ESWT) for upper extremity pain related to spasticity in patients with spinal cord injury.

6 times of ESWT (3,000 pulses per time, low energy under 0.3 mJ/mm\^2, tolerable range) on subscapularis and lesser and greater tuberlces of humerus to reduce pain in patients with brain damage

ESWT for Shoulder Pain in Patients With Brain Damage

The Effects of Extracorporeal Shockwave Therapy (ESWT) for Shoulder Pain in Patients With Brain Damage

Scoring scale consist of 5 pain scale and 8 disability scale, in %, 0 (best) to 100 (worst)

Bundang CHA Hospital

Principal professor of Rehabilitation Medicine

Central Nervous System Neoplasms

Nervous System Neoplasms

Analgesics

Central Nervous System Depressants

All Drugs and Chemicals

Remifentanil

Analgesics, Opioid

Narcotics

According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during head fixation. And, For this allocation of dose of remifentanil the investigators use biased coin design up-and-down method.

For the first patient, the dose of remifentanil would be fixed at 5.5ng/ml which we predict as EC90. And, step size of dose is 0.5ng/ml.

remifentanil

The purpose of this study is to estimate the EC90 of remifentanil blunting hemodynamic changes to head fixation in the patients undergoing neurosurgery.

The EC90 of Remifentanil Blunting Hemodynamic Changes to Head Fixation

The EC90 of Remifentanil Blunting Hemodynamic Changes to Head Fixation in the Patients Undergoing Neurosurgery

mean arterial blood pressure will be recorded at 2 minutes before fixation, 1 minute before fixation, highest value during immediately post-fixation periord, 1 minute after fixation, 2 minutes after fixation, 3 minutes after fixation, 4 minutes after fixation and 5 minutes after fixation.

heart rate will be recorded at 2 minutes before fixation, 1 minute before fixation, highest value during immediately post-fixation periord, 1 minute after fixation, 2 minutes after fixation, 3 minutes after fixation, 4 minutes after fixation and 5 minutes after fixation.

Seoul National University Hospital

professor

Rare Diseases

Hemorrhage

Glioma

Intracranial Hemorrhages

Thromboembolism

Venous Thromboembolism

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Thrombosis

Embolism

Embolism and Thrombosis

Vascular Diseases

Cerebrovascular Disorders

Neuroepithelioma

Fibrinolytic Agents

Anticoagulants

Heparin

Apixaban

Calcium heparin

Heparin, Low-Molecular-Weight

Tinzaparin

Dalteparin

patients who have switched from low molecular weight heparin (LMWH) to apixaban at the recommended dose of the treating physician.

FDA approved dose 10 mg twice daily (BID) for 7 days followed by 5 mg PO BID OR physician prescribed dose

The treating physician will initiate and prescribe the apixaban, the protocol will only observe and record intracranial pressure (ICP) and VTE incidences.

Observation of ICH and VTE

Stuart A Grossman, MD

Glioma patients with history of venous thromboembolism (VTE) treated on low molecular weight heparin (LMWH) and who decided with their physician to convert to Apixaban (oral drug) will be enrolled into our study and will collect data regarding recurrent VTE and Intracranial hemorrhage and the incidence of these events.

Primary Objectives To estimate the incidence of intracranial hemorrhage (ICH) in glioma patients with history of venous thromboembolism (VTE) after the conversion from low molecular weight heparin (LMWH) injections to oral Apixaban.

Secondary Objective To estimate the incidence of recurrent VTE in glioma patients with history of venous thromboembolism after the conversion from low molecular weight heparin (LMWH) injections to oral Apixaban.

Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban

Observe subject to determine the incidence of ICH during standard of care (SOC) observations.

Observe subject to determine the incidence of VTE during SOC observations.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
ESWT for Shoulder Pain in Patients With Brain Damage	NCT04320108	Brain Damage, H... Stroke Brain Tumor ICH	Extracorporeal ...	20 Years -	Bundang CHA Hospital
The EC90 of Remifentanil Blunting Hemodynamic Changes to Head Fixation	NCT01489137	Brain Tumor AVM ICH	remifentanil	20 Years - 65 Years	Seoul National University Hospital
ESWT for Shoulder Pain in Patients With Brain Damage	NCT04320108	Brain Damage, H... Stroke Brain Tumor ICH	Extracorporeal ...	20 Years -	Bundang CHA Hospital
Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban	NCT04895553	Glioma, Maligna...	Observation of ...	18 Years -	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Spots Global Cancer Trial Database for ich

Every month we try and update this database with for ich cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ich

Every month we try and update this database with for ich cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ich cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.